Bowen D - Search Results

1

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

Saft L, Karimi M, Ghaderi M, Matolcsy A, Mufti GJ, Kulasekararaj A, Göhring G, Giagounidis A, Selleslag D, Muus P, Sanz G, Mittelman M, Bowen D, Porwit A, Fu T, Backstrom J, Fenaux P, MacBeth KJ, Hellström-Lindberg E. Saft L, et al. Among authors: bowen d. Haematologica. 2014 Jun;99(6):1041-9. doi: 10.3324/haematol.2013.098103. Epub 2014 Mar 28. Haematologica. 2014. PMID: 24682512 Free PMC article.

2

Pathogenesis, etiology and epidemiology of myelodysplastic syndromes.

Aul C, Bowen DT, Yoshida Y. Aul C, et al. Among authors: bowen dt. Haematologica. 1998 Jan;83(1):71-86. Haematologica. 1998. PMID: 9542325 Review.

3

Best supportive care for the anaemia of myelodysplasia: inclusion of recombinant erythropoietin therapy?

Bowen DT, Hellstrom-Lindberg E. Bowen DT, et al. Leuk Res. 2001 Jan;25(1):19-21. doi: 10.1016/s0145-2126(00)00100-4. Leuk Res. 2001. PMID: 11137556 No abstract available.

4

Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes.

Tauro S, Hepburn MD, Bowen DT, Pippard MJ. Tauro S, et al. Among authors: bowen dt. Haematologica. 2001 Oct;86(10):1038-45. Haematologica. 2001. PMID: 11602409

5

Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes.

Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D, Parker J; UK MDS Guidelines Group. Bowen D, et al. Br J Haematol. 2003 Jan;120(2):187-200. doi: 10.1046/j.1365-2141.2003.03907.x. Br J Haematol. 2003. PMID: 12542475 Free article. No abstract available.

6

A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia.

Killick SB, Mufti G, Cavenagh JD, Mijovic A, Peacock JL, Gordon-Smith EC, Bowen DT, Marsh JC. Killick SB, et al. Among authors: bowen dt. Br J Haematol. 2003 Feb;120(4):679-84. doi: 10.1046/j.1365-2141.2003.04136.x. Br J Haematol. 2003. PMID: 12588356 Free article. Clinical Trial.

7

NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).

Fidler C, Watkins F, Bowen DT, Littlewood TJ, Wainscoat JS, Boultwood J. Fidler C, et al. Haematologica. 2004 Jul;89(7):865-6. Haematologica. 2004. PMID: 15257941

8

No increase in age-specific incidence of myelodysplastic syndromes.

Germing U, Strupp C, Kündgen A, Bowen D, Aul C, Haas R, Gattermann N. Germing U, et al. Among authors: bowen d. Haematologica. 2004 Aug;89(8):905-10. Haematologica. 2004. PMID: 15339672

9

Latency of onset of de novo myelodysplastic syndromes.

Wu PS, Hay AE, Thomas GE, Bowen DT. Wu PS, et al. Haematologica. 2004 Nov;89(11):1392-4. Haematologica. 2004. PMID: 15531463

10

Thalidomide therapy for low-risk Myelodysplasia.

Bowen D, MacIlwaine L, Cavanagh J, Killick S, Culligan D, Thomson E, Mufti G. Bowen D, et al. Leuk Res. 2005 Feb;29(2):235-6. doi: 10.1016/j.leukres.2004.05.017. Leuk Res. 2005. PMID: 15607375 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,484 results

Search Page